Paliperidon Teva (Paliperidone Palmitate)

Paliperidon Teva is an antipsychotic that works within the schizophrenia treatment pathway.

• Schizophrenia: helps control acute psychotic episodes and maintain symptom stability.
• Schizoaffective disorder: reduces mood‑related psychotic symptoms when used as maintenance therapy.
• Bipolar I disorder (maintenance): assists in preventing recurrence of manic or depressive episodes in patients already stabilized on other therapies.

• Paliperidone palmitate is a long‑acting pro‑drug of paliperidone that, after intramuscular administration, is slowly hydrolysed to release paliperidone. The active molecule antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in brain pathways implicated in psychosis and mood regulation.

Adverse reactions to paliperidone palmitate vary in frequency and severity.

Common Side Effects

• Injection site pain or erythema
• Headache
• Drowsiness or somnolence
• Weight gain
• Restlessness or akathisia
• Constipation

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe orthostatic hypotension
• Hyperglycaemia or new‑onset diabetes
• Seizures
• Elevated prolactin with galactorrhoea or menstrual disturbances

When prescribing Paliperidon Teva, clinicians should consider several safety aspects.

• Cardiovascular monitoring: patients with known cardiac disease or arrhythmias should be evaluated before use.
• Metabolic assessment: monitor weight, glucose and lipid profiles regularly.
• Movement disorders: watch for early signs of tardive dyskinesia or akathisia.
• Pregnancy and lactation: avoid ; ; 
• Renal function: dose adjustment may be needed for impaired renal clearance.
• Store at room temperature: keep in the original packaging ; protect  ​​  "

• Paliperidon Teva interacts  with     "  
• Major  
• t  
• t \\